Adaptive Biotechnologies Corporation (ADPT) fundamentals score
Throughout its history, Adaptive Biotechnologies has advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 5.2 out of 10, Mixed fundamentals
- Growth: 4.7/10
- Profitability: 4.3/10
- Financial health: 6.5/10
- Earnings quality: 6.8/10
- Valuation: 4.3/10
Scores are calculated from Adaptive Biotechnologies Corporation’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10